Antibacterial Discovery: Problems and Possibilities

Antibiotics: Targets, Mechanisms and Resistance

Volumn , Issue , 2013, Pages 23-52

  Silver, Lynn L ^a  

^a LL Silver Consulting LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84950299222     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527659685.ch2     Document Type: Chapter

References (110)

1. Payne, D.J., Gwynn, M.N., Holmes, D.J., and Pompliano, D.L. (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discovery, 6, 29-40.
2. Silver, L.L. (2011) Challenges of antibacterial discovery. Clin. Microbiol. Rev., 24, 71-109.
3. Livermore, D.M. (2011) Discovery research: the scientific challenge of finding new antibiotics. J. Antimicrob. Chemother., 66, 1941-1944.
4. Samant, S., Lee, H., Ghassemi, M., Chen, J., Cook, J.L., Mankin, A.S., and Neyfakh, A.A. (2008) Nucleotide biosynthesis is critical for growth of bacteria in human blood. PLoS Pathog., 4, e37.
5. Brinster, S., Lamberet, G., Staels, B., Trieu-Cuot, P., Gruss, A., and Poyart, C. (2009) Type II fatty acid synthesis is not a suitable antibiotic target for gram-positive pathogens. Nature, 458, 83-86.
6. Balemans, W., Lounis, N., Gilissen, R., Guillemont, J., Simmen, K., Andries, K., and Koul, A. (2010) Essentiality of FASII pathway for Staphylococcus aureus. Nature, 463, E3-E3.
7. Parsons, J.B. and Rock, C.O. (2011) Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery? Curr. Opin. Microbiol., 14, 544-549.
8. Chiang, S.L., Mekalanos, J.J., and Holden, D.W. (1999) In vivo genetic analysis of bacterial virulence. Annu. Rev. Microbiol., 53, 129-154.
9. Hill, C. (2012) Virulence or niche factors: what's in a name? J. Bacteriol., 194, 5725-5727.
10. Wright, G.D. (2010) The antibiotic resistome. Expert Opin. Drug Discovery, 5, 779-788.
11. Kearney, M., Palmer, S., Maldarelli, F., Shao, W., Polis, M.A., Mican, J.A., Rock-Kress, D., Margolick, J.B., Coffin, J.M., and Mellors, J.W. (2008) Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase. AIDS, 22, 497-501.
12. Robinson, M., Tian, Y., Delaney, W.E., and Greenstein, A.E. (2011) Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals. Proc. Natl. Acad. Sci. U.S.A., 108, 10290-10295.
13. Halfon, P. and Sarrazin, C. (2012) Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? Liver Int., 32 (Suppl. 1), 79-87.
14. Boltz, V.F., Ambrose, Z., Kearney, M.F., Shao, W., Kewalramani, V.N., Maldarelli, F., Mellors, J.W., and Coffin, J.M. (2012) Ultrasensitive allele-specific PCR reveals rare preexisting drug resistant variants and a large replicating virus population in macaques infected with RT-SHIV. J. Virol., 86, 12525-12530.
15. Coffin, J.M. (1995) HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science, 267, 483-489.
16. Diaz, L.A. Jr., Williams, R.T., Wu, J., Kinde, I., Hecht, J.R., Berlin, J., Allen, B., Bozic, I., Reiter, J.G., Nowak, M.A., Kinzler, K.W., Oliner, K.S., and Vogelstein, B. (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature, 486, 537-540.
17. Leder, K., Foo, J., Skaggs, B., Gorre, M., Sawyers, C.L., and Michor, F. (2011) Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia. PLoS ONE, 6, e27682.
18. Pfeifer, H., Wassmann, B., Pavlova, A., Wunderle, L., Oldenburg, J., Binckebanck, A., Lange, T., Hochhaus, A., Wystub, S., Bruck, P., Hoelzer, D., and Ottmann, O.G. (2007) Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL). Blood, 110, 727-734.
19. Andersson, D.I. and Hughes, D. (2009) Gene amplification and adaptive evolution in bacteria. Annu. Rev. Genet., 43, 167-195.
20. Silver, L. and Bostian, K. (1990) Screening of natural products for antimicrobial agents. Eur. J. Clin. Microbiol. Infect. Dis., 9, 455-461.
21. Silver, L.L. (2007) Multi-targeting by monotherapeutic antibacterials. Nat. Rev. Drug Discovery, 6, 41-55.
22. Silver, L.L. and Bostian, K.A. (1993) Discovery and development of new antibiotics: the problem of antibiotic resistance. Antimicrob. Agents Chemother., 37, 377-383.
23. Brotz-Oesterhelt, H. and Brunner, N.A. (2008) How many modes of action should an antibiotic have? Curr. Opin. Pharmacol., 8, 564-573.
24. Lange, R.P., Locher, H.H., Wyss, P.C., and Then, R.L. (2007) The targets of currently used antibacterial agents: lessons for drug discovery. Curr. Pharm. Des., 13, 3140-3154.
25. Silver, L.L. (2012) in Polypharmacology in Drug Discovery (ed. J. Peters), John Wiley & Sons, Inc., Hoboken, NJ, pp. 167-202.
26. Luria, S.E. and Delbrück, M. (1943) Mutations of bacteria from virus sensitivity to virus resistance. Genetics, 28, 491-511.
27. Couce, A. and Blázquez, J. (2011) Estimating mutation rates in lowreplication experiments. Mutation Res.-Fundam. Mol. Mech. Mutagen., 714, 26-32.
28. Rosche, W.A. and Foster, P.L. (2000) Determining mutation rates in bacterial populations. Methods, 20, 4-17.
29. Young, K. (2006) In vitro antibacterial resistance selection and quantitation. Curr. Protocols Pharmacol., 34, 13A.6.1-13A.6.22.
30. Tam, V.H., Louie, A., Deziel, M.R., Liu, W., and Drusano, G.L. (2007) The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob. Agents Chemother., 51, 744-777.
31. Gumbo, T., Louie, A., Deziel, M.R., Liu, W., Parsons, L.M., Salfinger, M., and Drusano, G.L. (2007) Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents Chemother., 51, 3781-3788.
32. Gumbo, T., Louie, A., Deziel, M.R., Parsons, L.M., Salfinger, M., and Drusano, G.L. (2004) Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis., 190, 1642-1651.
33. Srivastava, S., Sherman, C., Meek, C., Leff, R., and Gumbo, T. (2011) Pharmacokinetic mismatch does not lead to emergence of isoniazid or rifampin-resistant Mycobacterium tuberculosis, but better antimicrobial effect: a new paradigm for anti-tuberculosis drug scheduling. Antimicrob. Agents Chemother., 55, 5085-5089.
34. Gumbo, T., Louie, A., Deziel, M.R., and Drusano, G.L. (2005) Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. Antimicrob. Agents Chemother., 49, 3178-3181.
35. Gumbo, T., Louie, A., Liu, W., Ambrose, P.G., Bhavnani, S.M., Brown, D., and Drusano, G.L. (2007) Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J. Infect. Dis., 195, 194-201.
36. Hawser, S., Lociuro, S., and Islam, K. (2006) Dihydrofolate reductase inhibitors as antibacterial agents. Biochem. Pharmacol., 71, 941-948.
37. Frey, K.M., Viswanathan, K., Wright, D.L., and Anderson, A.C. (2012) Prospective screening of novel antibacterial inhibitors of dihydrofolate reductase for mutational resistance. Antimicrob. Agents Chemother., 56, 3556-3562.
38. Zhou, T., Commodore, L., Huang, W.-S., Wang, Y., Thomas, M., Keats, J., Xu, Q., Rivera, V.M., Shakespeare, W.C., Clackson, T., Dalgarno, D.C., and Zhu, X. (2011) Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistances. Chem. Biol. Drug Des., 77, 1-11.
39. Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M., and Ho, D.D. (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science, 271, 1582-1586.
40. Loeffler, J., Henke, N., Hebart, H., Schmidt, D., Hagmeyer, L., Schumacher, U., and Einsele, H. (2000) Quantification of fungal DNA by using fluorescence resonance energy transfer and the light cycler system. J. Clin. Microbiol., 38, 586-590.
41. Kurtz, M.B., Abruzzo, G., Flattery, A., Bartizal, K., Marrinan, J.A., Li, W., Milligan, J., Nollstadt, K., and Douglas, C.M. (1996) Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect. Immun., 64, 3244-3251.
42. König, C., Simmen, H., and Blaser, J. (1998) Bacterial concentrations in pus and infected peritoneal fluid-implications for bactericidal activity of antibiotics. J. Antimicrob. Chemother., 42, 227-232.
43. Breidenstein, E.B., de la Fuente-Nunez, C., and Hancock, R.E. (2011) Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol., 19, 419-426.
44. Nikaido, H. and Pagès, J.-M. (2012) Broad specificity efflux pumps and their role in multidrug resistance of gram-negative bacteria. FEMS Microbiol. Rev., 36, 340-363.
45. Li, X.Z. and Nikaido, H. (2009) Effluxmediated drug resistance in bacteria: an update. Drugs, 69, 1555-1623.
46. Nikaido, H. (2003) Molecular basis of bacterial outer membrane permeability revisited. Microbiol. Mol. Biol. Rev., 67, 593-656.
47. Silver, L.L. (2008) Are natural products still the best source for antibacterial discovery? The bacterial entry factor. Expert Opin. Drug Discovery, 3, 487-500.
48. Nichols, W.W. (2012) in Antibiotic Discovery and Development (eds T.J. Dougherty and M.J. Pucci), Springer, New York, pp. 849-879.
49. O'Shea, R.O. and Moser, H.E. (2008) Physicochemical properties of antibacterial compounds: implications for drug discovery. J. Med. Chem., 51, 2871-2878.
50. Macielag, M.J. (2012) in Antibiotic Discovery and Development (eds T.J. Dougherty and M.J. Pucci), Springer, New York, pp. 793-820.
51. Manchester, J.I., Buurman, E.T., Bisacchi, G.S., and McLaughlin, R.E. (2012) Molecular determinants of AcrBmediated bacterial efflux implications for drug discovery. J. Med. Chem., 55, 2532-2537.
52. Bolla, J.M., Alibert-Franco, S., Handzlik, J., Chevalier, J., Mahamoud, A., Boyer, G., Kiec-Kononowicz, K., and Pages, J.M. (2011) Strategies for bypassing the membrane barrier in multidrug resistant gram-negative bacteria. FEBS Lett., 585, 1682-1690.
53. Silver, L.L. (2012) in Antibiotic Discovery and Development (eds T.J. Dougherty and M.J. Pucci), Springer, New York, pp. 33-75.
54. Wong, W.R., Oliver, A.G., and Linington, R.G. (2012) Development of antibiotic activity profile screening for the classification and discovery of natural product antibiotics. Chem. Biol., 19, 1483-1495.
55. Koehn, F.E. (2008) in Progress in Drug Research (eds F. Petersen and R. Amstutz), Birkhäuser, Basel, pp. 175-210.
56. Baltz, R.H. (2007) Antimicrobials from actinomycetes: back to the future. Microbe, 2, 125-131.
57. De La Fuente, R., Sonawane, N.D., Arumainayagam, D., and Verkman, A.S. (2006) Small molecules with antimicrobial activity against E. coli and P. aeruginosa identified by high-throughput screening. Br. J. Pharmacol., 149, 551-559.
58. O'Neill, A.J. and Chopra, I. (2004) Preclinical evaluation of novel antibacterial agents by microbiological and molecular techniques. Expert Opin. Invest. Drugs, 13, 1045-1063.
59. Xu, H.H., Trawick, J.D., Haselbeck, R.J., Forsyth, R.A., Yamamoto, R.T., Archer, R., Patterson, J., Allen, M., Froelich, J.M., Taylor, I., Nakaji, D., Maile, R., Kedar, G.C., Pilcher, M., Brown-Driver, V., McCarthy, M., Files, A., Robbins, D., King, P., Sillaots, S., Malone, C., Zamudio, C.S., Roemer, T., Wang, L., Youngman, P.J., and Wall, D. (2010) Staphylococcus aureus TargetArray: comprehensive differential essential gene expression as a mechanistic tool to profile antibacterials. Antimicrob. Agents Chemother., 54, 3659-3670.
60. Wang, H., Claveau, D., Vaillancourt, J.P., Roemer, T., and Meredith, T.C. (2011) High-frequency transposition for determining antibacterial mode of action. Nat. Chem. Biol., 7, 720-729.
61. Gadebusch, H.H., Stapley, E.O., and Zimmerman, S.B. (1992) The discovery of cell wall active antibacterial antibiotics. Crit. Rev. Biotechnol., 12, 225-243.
62. Singh, S.B., Young, K., and Miesel, L. (2011) Screening strategies for discovery of antibacterial natural products. Expert Rev. Anti-Infect. Ther., 9, 589-613.
63. Mills, S.D. and Dougherty, T.J. (2012) in Antibiotic Discovery and Development (eds T.J. Dougherty and M.J. Pucci), Springer, New York, pp. 901-929.
64. Fischer, H.P., Brunner, N.A., Wieland, B., Paquette, J., Macko, L., Ziegelbauer, K., and Freiberg, C. (2004) Identification of antibiotic stress-inducible promoters: a systematic approach to novel pathway-specific reporter assays for antibacterial drug discovery. Genome Res., 14, 90-98.
65. Hutter, B., Fischer, C., Jacobi, A., Schaab, C., and Loferer, H. (2004) Panel of Bacillus subtilis reporter strains indicative of various modes of action. Antimicrob. Agents Chemother., 48, 2588-2594.
66. Mesak, L.R., Qi, S., Villanueva, I., Miao, V., and Davies, J. (2010) Staphylococcus aureus promoter-lux reporters for drug discovery. J. Antibiot., 63, 492-498.
67. Moir, D.T., Di, M., Moore, R.A., Schweizer, H.P., and Woods, D.E. (2008) Cellular reporter screens for inhibitors of Burkholderia pseudomallei targets in Pseudomonas aeruginosa. Trans. R. Soc. Trop. Med. Hyg., 102, S152-S162.
68. Mondal, R., Chanda, P.K., Bandhu, A., Jana, B., Lee, C.Y., and Sau, S. (2010) Detection of the cell wall-affecting antibiotics at sublethal concentrations using a reporter Staphylococcus aureus harboring drp35 promoter-lacZ transcriptional fusion. BMB Rep., 43, 468-473.
69. Forsyth, R.A., Haselbeck, R.J., Ohlsen, K.L., Yamamoto, R.T., Xu, H., Trawick, J.D., Wall, D., Wang, L., Brown-Driver, V., Froelich, J.M., Kedar, G.C., King, P., McCarthy, M., Malone, C., Misiner, B., Robbins, D., Tan, Z., Zhu, Z.-y., Carr, G., Mosca, D.A., Zamudio, C., Foulkes, J.G., and Zyskind, J.W. (2002) A genome-wide strategy for the identification of essential genes in Staphylococcus aureus. Mol. Microbiol., 43, 1387-1400.
70. Ji, Y., Zhang, B., Van, S.F., Horn, W.P., Woodnutt, G., Burnham, M.K.R., and Rosenberg, M. (2001) Identification of critical staphylococcal genes using conditional phenotypes generated by antisense RNA. Science, 293, 2266-2269.
71. DeVito, J.A., Mills, J.A., Liu, V.G., Agarwal, A., Sizemore, C.F., Yao, Z., Stoughton, D.M., Cappiello, M.G., Barbosa, M.D.F.S., and Foster, L.A. (2002) An array of target-specific screening strains for antibacterial discovery. Nat. Biotechnol., 20, 478-483.
72. Young, K., Jayasuriya, H., Ondeyka, J.G., Herath, K., Zhang, C., Kodali, S., Galgoci, A., Painter, R., Brown-Driver, V., Yamamoto, R., Silver, L.L., Zheng, Y., Ventura, J.I., Sigmund, J., Ha, S., Basilio, A., Vicente, F., Tormo, J.R., Pelaez, F., Youngman, P., Cully, D., Barrett, J.F., Schmatz, D., Singh, S.B., and Wang, J. (2006) Discovery of FabH/FabF inhibitors from natural products. Antimicrob. Agents Chemother., 50, 519-526.
73. Wang, J., Soisson, S.M., Young, K., Shoop, W., Kodali, S., Galgoci, A., Painter, R., Parthasarathy, G., Tang, Y.S., Cummings, R., Ha, S., Dorso, K., Motyl, M., Jayasuriya, H., Ondeyka, J., Herath, K., Zhang, C., Hernandez, L., Allocco, J., Basilio, A., Tormo, J.R., Genilloud, O., Vicente, F., Pelaez, F., Colwell, L., Lee, S.H., Michael, B., Felcetto, T., Gill, C., Silver, L.L., Hermes, J.D., Bartizal, K., Barrett, J., Schmatz, D., Becker, J.W., Cully, D., and Singh, S.B. (2006) Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature, 44, 358-361.
74. Wang, J., Kodali, S., Lee, S.H., Galgoci, A., Painter, R., Dorso, K., Racine, F., Motyl, M., Hernandez, L., Tinney, E., Colletti, S.L., Herath, K., Cummings, R., Salazar, O., Gonzalez, I., Basilio, A., Vicente, F., Genilloud, O., Pelaez, F., Jayasuriya, H., Young, K., Cully, D.F., and Singh, S.B. (2007) Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties. Proc. Natl. Acad. Sci. U.S.A., 104, 7612-7616.
75. Painter, R., Goetz, M., Arocho, M., Gill, C., Allocco, J., Nare, B., Powles, M., and Young, K. (2011) Elucidation of Dnae as the antibacterial target of the natural product, nargenicin. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy Conference, Chicago, Illinois, Presentation Abstract C1-612.
76. Huber, J., Donald, R.G.K., Lee, S.H., Jarantow, L.W., Salvatore, M.J., Meng, X., Painter, R., Onishi, R.H., Occi, J., Dorso, K., Young, K., Park, Y.W., Skwish, S., Szymonifka, M.J., Waddell, T.S., Miesel, L., Phillips, J.W., and Roemer, T. (2009) Chemical genetic identification of peptidoglycan inhibitors potentiating carbapenem activity against methicillin-resistant Staphylococcus aureus. Chem. Biol., 16, 837-848.
77. Miesel, L., Greene, J., and Black, T.A. (2003) Genetic strategies for antibacterial drug discovery. Nat. Rev. Genet., 4, 442-456.
78. Therien, A.G., Huber, J.L., Wilson, K.E., Beaulieu, P., Caron, A., Claveau, D., Deschamps, K., Donald, R.G., Galgoci, A.M., Gallant, M., Gu, X., Kevin, N.J., Lafleur, J., Leavitt, P.S., Lebeau-Jacob, C., Lee, S.S., Lin, M.M., Michels, A.A., Ogawa, A.M., Painter, R.E., Parish, C.A., Park, Y.W., Benton-Perdomo, L.L., Petcu, M., Phillips, J.W., Powles, M.A., Skorey, K.I., Tam, J., Tan, C.M., Young, K., Wong, S., Waddell, S.T., and Miesel, L. (2012) Broadening the spectrum of β-lactam antibiotics through inhibition of signal peptidase type I. Antimicrob. Agents Chemother., 56, 4662-4670.
79. Kuroda, Y., Okuhara, M., Goto, T., Iguchi, E., Kohsaka, M., Aoki, H., and Imanaka, H. (1980) FR-900130, a novel amino acid antibiotic. I. Discovery, taxonomy, isolation, and properties. J. Antibiot., 33, 125-131.
80. Tomasz, A. (1990) in Molecular Biology of the Staphylococci (eds R. Skurray and R. Novick), VCH Publishers, New York, pp. 565-583.
81. Berger-Bächi, B., Strässle, A., Gustafson, J.E., and Kayser, F.H. (1992) Mapping and characterization of multiple chromosomal factors involved in methicillin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother., 36, 1367-1373.
82. Lipinski, C., Lombardo, F., Dominy, B., and Feeney, P. (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev., 23, 3-25.
83. Babaoglu, K., Simeonov, A., Irwin, J.J., Nelson, M.E., Feng, B., Thomas, C.J., Cancian, L., Costi, M.P., Maltby, D.A., Jadhav, A., Inglese, J., Austin, C.P., and Shoichet, B.K. (2008) Comprehensive mechanistic analysis of hits from high-throughput and docking screens against β-lactamase. J. Med. Chem., 51, 2502-2511.
84. Paolini, G.V., Shapland, R.H.B., van Hoorn, W.P., Mason, J.S., and Hopkins, A.L. (2006) Global mapping of pharmacological space. Nat. Biotechnol., 24, 805-815.
85. Baell, J.B. and Holloway, G.A. (2010) New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem., 53, 2719-2740.
86. Williams, D., Stone, M., Hauck, P., and Rahman, S. (1989) Why are secondary metabolites (natural products) biosynthesized? J. Nat. Prod., 52, 1189-1208.
87. Sukuru, S.C.K., Jenkins, J.L., Beckwith, R.E.J., Scheiber, J., Bender, A., Mikhailov, D., Davies, J.W., and Glick, M. (2009) Plate-based diversity selection based on empirical HTS data to enhance the number of hits and their chemical diversity. J. Biomol. Screening., 14, 690-699.
88. Arndt, C., Cruz, M.C., Cardenas, M.E., and Heitman, J. (1999) Secretion of FK506/FK520 and rapamycin by Streptomyces inhibits the growth of competing Saccharomyces cerevisiae and Cryptococcus neoformans. Microbiology, 145, 1989-2000.
89. Lorenz, R.T. and Parks, L.W. (1990) Effects of lovastatin (mevinolin) on sterol levels and on activity of azoles in Saccharomyces cerevisiae. Antimicrob. Agents Chemother., 34, 1660-1665.
90. Zhang, C. and DeLisi, C. (1998) Estimating the number of protein folds. J. Mol. Biol., 284, 1301-1305.
91. Koehn, F.E. and Carter, G.T. (2005) The evolving role of natural products in drug discovery. Nat. Rev. Drug Discovery, 4, 206-220.
92. Brakhage, A.A., Al-Abdallah, Q., Tüncher, A., and Spröte, P. (2005) Evolution of β-lactam biosynthesis genes and recruitment of trans-acting factors. Phytochemistry, 66, 1200-1210.
93. Seow, K.T., Meurer, G., Gerlitz, M., Wendt-Pienkowski, E., Hutchinson, C.R., and Davies, J. (1997) A study of iterative type II polyketide synthases, using bacterial genes cloned from soil DNA: a means to access and use genes from uncultured microorganisms. J. Bacteriol., 179, 7360-7368.
94. Feng, Z., Kallifidas, D., and Brady, S.F. (2011) Functional analysis of environmental DNA-derived type II polyketide synthases reveals structurally diverse secondary metabolites. Proc. Natl. Acad. Sci. U.S.A., 108, 12629-12634.
95. Lewis, K., Epstein, S., D'Onofrio, A., and Ling, L.L. (2010) Uncultured microorganisms as a source of secondary metabolites. J. Antibiot., 63, 468-476.
96. Schmid, M.B. (2012) in Antibiotic Discovery and Development (eds T.J. Dougherty and M.J. Pucci), Springer, New York, pp. 969-984.
97. Finn, J. (2012) in Structure-Based Drug Discovery; Methods in Molecular Biology (ed. L.W. Tari), Springer, Clifton, NJ, pp. 291-319.
98. Agarwal, A.K. and Fishwick, C.W. (2010) Structure-based design of antiinfectives. Ann. N. Y. Acad. Sci., 1213, 20-45.
99. Agarwal, A., Louise-May, S., Thanassi, J.A., Podos, S.D., Cheng, J., Thoma, C., Liu, C., Wiles, J.A., Nelson, D.M., Phadke, A.S., Bradbury, B.J., Deshpande, M.S., and Pucci, M.J. (2007) Small molecule inhibitors of E. coli primase, a novel bacterial target. Bioorg. Med. Chem. Lett., 17, 2807-2810.
100. Miller, J.R., Dunham, S., Mochalkin, I., Banotai, C., Bowman, M., Buist, S., Dunkle, B., Hanna, D., Harwood, H.J., Huband, M.D., Karnovsky, A., Kuhn, M., Limberakis, C., Liu, J.Y., Mehrens, S., Mueller, W.T., Narasimhan, L., Ogden, A., Ohren, J., Prasad, J.V.N.V., Shelly, J.A., Skerlos, L., Sulavik, M., Thomas, V.H., VanderRoest, S., Wang, L., Wang, Z., Whitton, A., Zhu, T., and Stover, C.K. (2009) A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore. Proc. Natl. Acad. Sci. U. S. A., 106, 1737-1742.
101. Mochalkin, I., Miller, J.R., Narasimhan, L., Thanabal, V., Erdman, P., Cox, P.B., Prasad, J.V.N.V., Lightle, S., Huband, M.D., and Stover, C.K. (2009) Discovery of antibacterial biotin carboxylase inhibitors by virtual screening and fragment-based approaches. ACS Chem. Biol., 4, 473-483.
102. Brötz-Oesterhelt, H., Knezevic, I., Bartel, S., Lampe, T., Warnecke-Eberz, U., Ziegelbauer, K., Häbich, D., and Labischinski, H. (2003) Specific and potent inhibition of NAD+-dependent DNA ligase by pyridochromanones. J. Biol. Chem., 278, 39435-39442.
103. Stokes, S.S., Huynh, H., Gowravaram, M., Albert, R., Cavero-Tomas, M., Chen, B., Harang, J., Loch, J.T. III, Lu, M., Mullen, G.B., Zhao, S., Liu, C.-F., and Mills, S.D. (2011) Discovery of bacterial NAD+-dependent DNA ligase inhibitors: optimization of antibacterial activity. Bioorg. Med. Chem. Lett., 21, 4556-4560.
104. Mills, S.D., Eakin, A.E., Buurman, E.T., Newman, J.V., Gao, N., Huynh, H., Johnson, K.D., Lahiri, S., Shapiro, A.B., Walkup, G.K., Yang, W., and Stokes, S.S. (2011) Novel bacterial NAD+-dependent DNA ligase inhibitors with broad spectrum activity and antibacterial efficacy in vivo. Antimicrob. Agents Chemother., 55, 1088-1096.
105. Gu, W., Wang, T., Maltais, F., Ledford, B., Kennedy, J., Wei, Y., Gross, C.H., Parsons, J., Duncan, L., Arends, S.J., Moody, C., Perola, E., Green, J., and Charifson, P.S. (2012) Design, synthesis and biological evaluation of potent NAD+-dependent DNA ligase inhibitors as potential antibacterial agents. Part I: aminoalkoxypyrimidine carboxamides. Bioorg. Med. Chem. Lett., 22, 3693-3698.
106. Wang, T., Duncan, L., Gu, W., O'Dowd, H., Wei, Y., Perola, E., Parsons, J., Gross, C.H., Moody, C.S., Ryan Arends, S.J., and Charifson, P. (2012) Design, synthesis and biological evaluation of potent NAD+-dependent DNA ligase inhibitors as potential antibacterial agents. Part II: 4-Amino-pyrido[2,3-d]pyrimidin-5(8H)-ones. Bioorg. Med. Chem. Lett., 11, 3699-3703.
107. Podos, S.D., Thanassi, J.A., and Pucci, M.J. (2012) Mechanistic assessment of DNA ligase as an antibacterial target in Staphylococcus aureus. Antimicrob. Agents Chemother., 56, 4095-4102.
108. Trzoss, M., Bensen, D.C., Li, X., Chen, Z., Lam, T., Zhang, J., Creighton, C.J., Cunningham, M.L., Kwan, B., Stidham, M., Nelson, K., Driver, V., Castellano, A., Shaw, K.J., Lightstone, F.C., Wong, S.E., Nguyen, T.B., Finn, J., and Tari, L.W. (2012) Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), part II: development of inhibitors with broad spectrum, gram-negative antibacterial activity. Bioorg. Med. Chem. Lett., 23, 1537-1543.
109. Tari, L.W., Trzoss, M., Bensen, D.C., Li, X., Chen, Z., Lam, T., Zhang, J., Creighton, C.J., Cunningham, M.L., Kwan, B., Stidham, M., Shaw, K.J., Lightstone, F.C., Wong, S.E., Nguyen, T.B., Nix, J., and Finn, J. (2012) Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), part I: structure guided discovery and optimization of dual targeting agents with potent, broad spectrum enzymatic activity. Bioorg. Med. Chem. Lett., 23, 1529-1536.
110. Sams-Dodd, F. (2012) Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift. Drug Discov. Today, 18, 211-217.